A5211: PHASE II OF SCH417690, ORAL HIV-1 ENTRY INHIBITOR IN HIV

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。假设：在有治疗经验的hiv感染患者中，SCH 417690是安全的，通常耐受性良好，并且与含有利托那韦的抗逆转录病毒治疗方案同时使用时显示出抗逆转录病毒活性。主要目的：评估三种剂量水平的SCH 417690在当前含利托那韦抗逆转录病毒治疗失败的hiv感染者中14天以上的病毒学活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: In HIV-infected, treatment-experienced patients, SCH 417690 will be safe, be generally well-tolerated, and demonstrate antiretroviral activity when used concurrently with a ritonavir-containing antiretroviral regimen. Primary Objective: To evaluate the virologic activity over 14 days of three dose levels of SCH 417690 in HIV-infected, treatment-experienced subjects who are failing their current ritonavir-containing antiretroviral regimen.